

Late-breaking poster presentations (as of 9/20/23)

### Poster Session A

**Thursday, October 12 | 12:30 pm-4:00 pm**

**Level 2, Exhibit Hall D**

**LB\_A01:** *Rapidly cleared MCL1 inhibitor TTX-810 showing robust efficacy in preclinical tumor models with no effects on cardiomyocytes in vitro and in vivo.* Ulrike Rauh, Trueline Therapeutics Inc., Berlin, Germany.

**LB\_A02:** *Predicting breast cancer patients' response to neoadjuvant chemotherapy from the deconvolved transcriptome of different cell types in the tumor microenvironment.* Saugato Rahman Dhruba, National Cancer Institute, National Institutes of Health, Bethesda, MD United States.

**LB\_A03:** *Proximity ligation sequencing reveals novel and recurrent structural genomic variants in FFPE pancreatic ductal adenocarcinoma samples.* Abhishek Pandey, University of Colorado Comprehensive Cancer Center, Aurora, CO United States.

**LB\_A04:** *Quantitative digital spatial protein profiling of non-small cell lung cancer brain metastasis.* Tae Jung Kim, The Catholic University of Korea, Seoul, Korea, Republic of.

**LB\_A05:** *Coadministration of AZD 4573 and gilteritinib exhibits a potent activity in FLT3 inhibitor-sensitive and -resistant AML cells.* Mohamed Rahmani, College of Medicine, Sharjah Institute for Medical Research, University of Sharjah; College of Medicine & Health Sciences, Center for Biotechnology, Khalifa University., Abu Dhabi, United Arab Emirates.

**LB\_A07:** *Repotrectinib in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial.* Jessica J Lin, Massachusetts General Hospital, Harvard Medical School, Boston, MA United States.

**LB\_A10:** *Efficacy of ATR inhibitor berzosertib plus topotecan or topotecan alone in patients with relapsed small cell lung cancer: A randomized clinical trial.* Nobuyuki Takahashi, National Cancer Institute, Center for Cancer Research, Bethesda, MD United States.

**LB\_A12:** *Initial Results from 2 Phase I Studies of NMS-03305293, a Selective PARP1 Inhibitor.* Lisa Mahnke, Nerviano Medical Sciences Inc., Boston, MA United States.

**LB\_A13:** *Phase 1 dose expansion results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) in platinum-resistant ovarian cancer.* Gerald Steven Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO United States.

**LB\_A14:** *Factors associated with enrollment, participation, and survival of patients on early phase cancer clinical trials.* Deborah B. Doroshow, Icahn School of Medicine at Mount Sinai, New York, NY United States.

**LB\_A16:** *Dareon<sup>TM</sup>-5: An open-label Phase II trial of BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas.* Valentina Gambardella, Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia; CIBERONC, Instituto de Salud Carlos III, Madrid, Valencia, Spain.

LB\_A17: *Trial in progress: First-in-human phase I dose-escalation study of a novel Bicycle toxin conjugate (BT5528) targeting EphA2 in patients with advanced solid tumors.* Elisa Fontana, Sarah Cannon Research Institute, London, United Kingdom.

LB\_A19: *Genome-wide CRISPR/Cas9 screens for the identification of targeted vulnerabilities in PARP inhibitor-resistant PARG;BRCA2-deficient tumor cells: A focus on EXO1/FEN1-mediated DNA repair.* Christina Andronikou, Netherlands Cancer Institute, Amsterdam, Netherlands.

LB\_A20: *Overcoming Cancer Drug Resistance with AI-Designed RNA Epigenetic Inhibitors.* Jason X. Cheng, University of Chicago, Chicago, IL United States.

LB\_A21: *NCI60 HTS384: The next phase of the NCI60 screen.* Beverly A. Teicher, NCI, Rockville, MD United States.

LB\_A22: *Advancing personalized therapies for small cell lung cancer: Exploring HER2-targeting antibody-drug conjugates (ADCs) and SLFN11 biomarker insights.* Ali H. Ibrahim, MD Anderson Cancer Center, Houston, TX United States.

LB\_A23: *The role of SMARCA1 in Rhabdomyosarcoma and Skeletal Muscle Differentiation.* Ashwaq K. Aljabri, NIH, Frederick, MD United States.

LB\_A24: *Baicalein suppresses tumorigenesis of the ER positive of breast cancer cells by targeting multiple signaling pathways.* Besa Xhabija, University of Michigan- Dearborn, Dearborn, MI United States.

LB\_A25: *Updated Phase 1 results from the PYNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation.* Alison M. Schram, Memorial Sloan Kettering Cancer Center, New York, NY United States.